Daily Judi: Wednesday, August 31, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
The Food and Drug Administration has approved Moderna and Pfizer's new COVID-19 booster shots that target the active Omicron variants BA.4 and BA.5. Pfizer partnered with BioNTech to develop its vaccine, which is authorized for people 12 and older. Moderna's vaccine is a single-shot booster authorized for people 18 and up. (NPR)
Theranica, an Israel- and New Jersey-based maker of digital therapeutics, landed a $45 million round of investment for its wearable drug-free technology, which is designed to treat people with migraines. (Fierce Biotech)
Needs and priorities, budget, location, providers and vendors—Kamila Novak, of KAN Consulting, details a strategy for small sponsors to consider when selecting a CRO. (Clinical Leader)
The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!
We also hope to see you this September 13-14, in Boston, for DPHARM: Disruptive Innovations to Advance Clinical Trials, walking distance from our North End headquarters.
“I work mainly with one CRO, and they thank us for being proactive, and for our precise attention. We get a lot of appreciation from their whole team as we help them with their deliverable.”
–Jess, Program Manager
Judi empowers and enhances the world's clinical trial ecosystems. Our cloud-based platform enables complex end-to-end process management and collaboration. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.